• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2023 Mar 1;S1201-9712(23)00071-1.
doi: 10.1016/j.ijid.2023.02.022. Online ahead of print.
Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides antibodies for the neonate


S J M Zilver[SUP] 1 [/SUP], C J M de Groot[SUP] 2 [/SUP], M Grobben[SUP] 3 [/SUP], S Remmelzwaal[SUP] 4 [/SUP], E Burgers[SUP] 5 [/SUP], D Nunez Velasco[SUP] 6 [/SUP], H G Juncker[SUP] 7 [/SUP], B J van Keulen[SUP] 7 [/SUP], J B van Goudoever[SUP] 7 [/SUP], R A de Leeuw[SUP] 6 [/SUP], M J van Gils[SUP] 3 [/SUP], C Ris-Stalpers[SUP] 2 [/SUP], E van Leeuwen[SUP] 2 [/SUP]



Affiliations
Free PMC article

Abstract

Objectives: Preventative measures against Coronavirus Disease 2019 (COVID-19) are essential for pregnant women; they are particularly vulnerable to emerging infectious pathogens due to alterations in their physiology. We aimed to determine the optimum timing of vaccination to protect pregnant women and their neonates from COVID-19.
Methods: A prospective observational longitudinal cohort study in pregnant women who received COVID-19 vaccination. We collected blood samples to evaluate levels of anti-spike, receptor binding domain (RBD) and nucleocapsid antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before vaccination, and 15 days after first and second vaccination. We determined neutralizing antibodies from mother-infant dyads in maternal and umbilical cord blood at birth. If available, IgA was measured in human milk.
Results: We included 178 pregnant women. Median anti-spike IgG levels increased significantly from 1.8 to 5431 binding antibody units/milliliter (BAU/mL) and RBD from 6 to 4466 BAU/mL. Virus neutralization showed similar results between different weeks' gestations at vaccination (p > 0.3).
Conclusions: We advise vaccination in the early second trimester of pregnancy for the optimum balance between maternal antibody response and placental antibody transfer to the neonate.
 
Back
Top Bottom